• Azithromycin: Workflows for Infection and Senolysis

  2026-09-29

  Azithromycin supports distinct research workflows, from resistance benchmarking and bacterial infection research to senescent-fibroblast screening. This guide connects its ribosome-directed activity with practical assay design, solvent control, impurity monitoring, and translational limitations.

• Lypressin Acetate: A Mechanism-to-Assay Guide

  2026-09-29

  Lypressin acetate is a multifunctional vasopressin receptor agonist whose receptor profile can guide better antidiuretic, vasoconstriction, and antiviral assay design. This mechanism-to-assay perspective connects molecular identity, endpoint selection, handling, and evidence maturity.

• M. pneumoniae Resistance in Beijing Children, 2023

  2026-09-28

  This 2024 study linked phenotypic susceptibility testing with molecular typing and clinical data to characterize macrolide-resistant Mycoplasma pneumoniae in children from Beijing. All 62 isolates carried the A2063G mutation and were resistant to erythromycin and azithromycin, emphasizing the need for local surveillance and non-macrolide treatment research.

• gamma-Glu-Cys Workflows for Glutathione Research

  2026-09-28

  Use gamma-Glu-Cys (γ-Glu-Cys) to probe glutathione synthesis directly, then pair substrate-controlled assays with carefully matched microbial or plant experiments. The key is to separate what a defined enzyme assay can establish from what whole-cell peptide production depends on: strain, medium, and substrate availability.

• Beyond DNA Repair: Mapping ATM Inhibition

  2026-09-27

  ATM inhibition can reshape more than DNA damage signaling. Explore how AZD0156 supports selective ATM kinase research and how to test the emerging link between DNA damage response, nutrient scavenging, and cancer cell adaptation.

• Cabozantinib (XL184) Workflows for RCC Signaling

  2026-09-26

  Use Cabozantinib (XL184) to compare acute kinase suppression with chronic signaling adaptation in cancer models—not just to measure short-term growth effects. This practical guide connects phosphoproteomics, motility assays, and antiangiogenic readouts while highlighting controls that help distinguish drug response from adaptation.

• AZD0156: ATM Kinase Inhibitor Workflows

  2026-09-25

  Use AZD0156 to test how ATM inhibition changes DNA damage signaling, checkpoint responses, and sensitivity to double-strand-break-inducing treatments. This practical workflow pairs dose finding with orthogonal pathway readouts and phenotype assays, helping distinguish target-related effects from model or handling artifacts.

• Gamithromycin PK/PD in Rabbit Pasteurellosis

  2026-09-25

  Wei and colleagues link rabbit pharmacokinetics of gamithromycin with its concentration-dependent activity against Pasteurella multocida, identifying plasma AUC24h/MIC targets associated with bacteriostasis, bactericidal activity, and eradication. The results offer a quantitative basis for evaluating gamithromycin in rabbits, while remaining specific to the studied drug, pathogen, and experimental setting.

• Lovastatin: From Mevalonate Biology to Translation

  2026-09-24

  Lovastatin offers a practical way to perturb mevalonate production and study the resulting effects on cell growth, survival, and immune-cell function. This article connects its mechanism to translational study design, highlights evidence and limitations, and outlines ways to build more interpretable experiments.

• SRT1720 HCl: SIRT1 and Bone Repair

  2026-09-24

  SRT1720 HCl is a research reagent associated with SIRT1 activation, but published assay results show that its activity depends on experimental context. A 2026 study links SIRT1 activation to endothelial and osteogenic responses and improved repair in aged bone models; its supplied summary does not identify SRT1720 as the activator used.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-09-23

  AZD8055 is an ATP-competitive mTOR inhibitor for studying mTORC1 and mTORC2 signaling in controlled preclinical experiments. Its poor water solubility requires DMSO-based handling, and it should not be used to support clinical efficacy claims.

• REV1–DHX36 Control of G4 DNA Replication

  2026-09-23

  The 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. Its two-tiered model explains how cells tolerate stabilized G4 structures and provides a mechanistic framework for studying replication stress and DNA damage response signaling.

• AZD2461: Practical PARP Inhibitor Assay Design

  2026-09-22

  AZD2461 is a novel PARP inhibitor for dissecting DNA repair pathway modulation, cytotoxicity, and resistance in breast cancer research. This workflow separates growth inhibition from true cell killing while using target-engagement and Pgp-resistance readouts to improve interpretation.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-09-22

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling in cellular and animal models. It is useful for mechanistic and pharmacodynamic research, but its water insolubility, solution-handling requirements, lack of directly matched paper evidence here, and limited clinical benefit mean it should not be used to support clinical efficacy conclusions.

• Ciclesonide: An Assay-First Mechanistic Guide

  2026-09-21

  Ciclesonide research depends on separating prodrug activation, glucocorticoid receptor binding, and downstream anti-inflammatory effects. This assay-first guide also clarifies what the 2026 ERAD study does—and does not—demonstrate about desisobutyryl-ciclesonide and targeted protein degradation.

8115 records 1/541 page Next 12345 下5页 Last page